市場調査報告書：薬物治療：内分泌疾患／代謝性疾患

Abstract

INTRODUCTION

The aim of this report is to provide a range of information - from detailed market analyses through industry trends - to quantify, qualify, and compare prescription products on the market and in development for the treatment of selected endocrine and metabolic disorders. There is a correlation between several endocrine and metabolic disorders, and recently there has been considerable emphasis put on metabolic syndrome, which comprises several interrelated endocrine and metabolic disorders. The metabolic components of cardiovascular disease and obesity, for example, are linked in numerous ways that reflect the impact each has on the other. Reduction in obesity reduces the incidence of diabetes, and both of these conditions, independently, are major contributors to cardiovascular disease.

SCOPE OF STUDY

This report contains:

The major current and emerging markets for prescription drugs for endocrine and metabolic diseases, including hypertension, infertility, thyroid diseases, hypercholesterolemia, and obesity
Historical market data from 2004, 2005, and 2006, in addition to five-year market forecasts with compounded annual growth rates through 2011
Discusses applications as well as current and upcoming technology and trends
Provides detailed patent analysis and profiles of the major companies in the biotechnology and pharmaceutical industries that provide products for the diseases covered in this report.

METHODOLOGY

The base year for this study is 2006. Figures are based on revenue figures at the manufacturer' s level and are projected at 2006 dollar value - that is, inflation is not computed into the projection figures.

Data and trends obtained to prepare this study were derived from information obtained from pharmaceutical product managers, marketing strategists, research executives, and others at leading biotechnology and pharmaceutical companies that have products used in the treatment of the diseases covered in this report, or which have products in development for these markets.

INFORMATION SOURCES

The information and analyses presented in this report are based on an extensive survey of the pharmaceutical industries, as well as a detailed examination of published literature and reports obtained from regulatory authorities, medical research institutions, pharmaceutical trade associations, and national and world health organizations. Key information from the business literature was used to obtain expert opinion on commercial potential and market sizes from industry professionals.

INTRODUCTION
- OBJECTIVES AND GOALS OF THE STUDY
- CONTRIBUTION OF THE STUDY AND FOR WHOM
- SCOPE AND CONTENT
- METHODOLOGY
- INFORMATION SOURCES
- ABOUT THE AUTHOR
- RELATED BCC PUBLICATIONS
- DISCLAIMER
EXECUTIVE SUMMARY
- Summary Table:
- GLOBAL MARKETS FOR PRESCRIPTION DRUGS TO TREAT ENDOCRINE AND METABOLIC DISEASES COVERED IN THIS REPORT, THROUGH 2011 ($ MILLIONS)
- Summary Figure:
- GLOBAL MARKETS FOR PRESCRIPTION DRUGS TO TREAT ENDOCRINE AND METABOLIC DISEASES COVERED IN THIS REPORT, THROUGH 2011 ($ MILLIONS)
OVERVIEW
- THE ENDOCRINE SYSTEM
  - ROLE OF THE HYPOTHALAMUS IN ENDOCRINE FUNCTION
- Table 1 HYPOTHALAMIC NEUROHORMONES
  - TYPES AND ACTIVITIES OF NEUROHORMONES PRODUCED BY THE HYPOTHALAMUS
- ENDOCRINE DISEASES
  - HYPERTENSION
    - Hypertension (Continued)
    - The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
- Table 2 EFFECTS OF ANTIHYPERTENSIVE AGENTS ON SELECTED CORONARY RISK FACTORS
  - The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
- Table 3 CLASSIFICATION OF BLOOD PRESSURE FOR ADULTS AGE 18 YEARS AND OLDER
  - INFERTILITY
    - Prevalence of Infertility
    - Causes of Infertility
      - Infertility Factors
      - Female Factors
        
        Tubal Factors
        Ovulation Factors
        Amenorrhea
        Amenorrhea (Continued)
        Amenorrhea (Continued)
        Anovulation
- Table 4 CLASSIFICATION OF CHRONIC ANOVULATION
  - Luteal Phase Dysfunction
    - Endometriosis
      - Endometriosis (Continued)
    - Fibroids
    - Other and Unknown Factors
      - Cervical Factors
      - The Role of Relaxin
      - Male Factors
        
        Varicocele
        Genetic Factors
        Microdeletions of the Y-Chromosome
        Congenital Bilateral Absence of the Vas Deferens
        A-MYB Gene and its Relation to Male Infertility
        Reduced Spermatogenesis
        Hypogonadism
        Environmental Factors
        Treatment Protocols
- THYROID DISORDERS
  - Functions of the Thyroid Hormones
  - Clinical Evaluation of Thyroid Disorders
- Table 5 LABORATORY EVALUATION OF THYROID DISORDERS
  - Hyperthyroidism
- Table 6 CLASSIFICATION OF HYPERTHYROIDISM
  - Graves' Disease
  - Hypothyroidism
  - Thyroiditis
- METABOLIC DISEASES
  - HYPERCHOLESTEROLEMIA
    - Hypercholesterolemia (Continued)
    - Hypercholesterolemia (Continued)
    - Relationship of Cholesterol to Cardiovascular Disease
  - OBESITY
    - Drug Treatment for Obesity
    - Alternative Treatments for Obesity
  - METABOLIC SYNDROME
- Table 7 BODY MASS INDEX RATIOS AND CLASSIFICATION OF OBESITY
  - METABOLIC SYNDROME (CONTINUED)
ENDOCRINE DISEASES - APPLICATIONS AND PRODUCTS
- HYPERTENSION
  - PRESCRIPTION DRUGS FOR THE TREATMENT OF HYPERTENSION
    - Adrenergic Inhibitors
- Table 8 SELECTED ADRENERGIC INHIBITORS: PRECAUTIONS AND SIDE EFFECTS
  - The Market for Adrenergic Inhibitors
- Table 9 GLOBAL MARKET FOR ADRENERGIC INHIBITORS, THROUGH 2011 ($ MILLIONS)
- Figure 1 GLOBAL MARKET FOR ADRENERGIC INHIBITORS, 2004-2011 ($ MILLIONS)
  - Angiotensin-Converting Enzyme Inhibitors
    - Angiotensin-Converting Enzyme Inhibitors (Continued)
- Table 10 SELECTED ACE INHIBITORS: PRECAUTIONS AND SIDE EFFECTS
  - The Market for ACE Inhibitors
- Table 11 GLOBAL MARKET FOR ACE INHIBITORS, THROUGH 2011 ($ MILLIONS)
- Figure 2 GLOBAL MARKET FOR ACE INHIBITORS, 2004-2011 ($ MILLIONS)
  - Angiotensin II Receptor Antagonists
    - The Difference Between ACE Inhibitors and Angiotensin II Inhibitors
    - The Market for Angiotensin II Inhibitors
- Table 12 GLOBAL MARKET FOR ANGIOTENSIN II INHIBITORS, THROUGH 2011 ($ MILLIONS)
- Figure 3 GLOBAL MARKET FOR ANGIOTENSIN II INHIBITORS, 2004-2011 ($ MILLIONS)
  - Beta Blockers
- Table 13 SELECTED BETA BLOCKERS: PRECAUTIONS AND SIDE EFFECTS
  - Usage Trends of Beta Blockers
  - The Market for Beta Blockers
- Table 14 GLOBAL MARKET FOR BETA BLOCKERS, THROUGH 2011 ($ MILLIONS)
- Figure 4 GLOBAL MARKET FOR BETA BLOCKERS, 2004-2011 ($ MILLIONS)
  - Calcium Channel Blockers
- Table 15 SELECTED CALCIUM CHANNEL BLOCKERS: PRECAUTIONS AND SIDE EFFECTS
- Table 15 (CONTINUED)
  - Calcium Channel Blocker Usage
  - The Market for Calcium Channel Blockers
- Table 16 GLOBAL MARKET FOR CALCIUM CHANNEL BLOCKERS, THROUGH 2011 ($ MILLIONS)
- Figure 5 GLOBAL MARKET FOR CALCIUM CHANNEL BLOCKERS, 2004-2011 ($ MILLIONS)
  - Combination Products
    - The Market for Combination Antihypertensive Products
- Table 17 GLOBAL MARKET FOR COMBINATION ANTIHYPERTENSIVE DRUGS, THROUGH 2011 ($ MILLIONS)
- Figure 6 GLOBAL MARKET FOR COMBINATION ANTIHYPERTENSIVE DRUGS, 2004-2011 ($ MILLIONS)
  - Treatment Regimens
  - The Market for Selected Drugs to Treat Hypertension
- Table 18 GLOBAL MARKET FOR SELECTED PRESCRIPTION PRODUCTS TO TREAT HYPERTENSION BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 19 U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT HYPERTENSION, THROUGH 2011 ($ MILLIONS)
- Figure 7 U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT HYPERTENSION, 2004-2011 ($ MILLIONS)
  - Products in Development for the Treatment of Hypertension
- Table 20 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF HYPERTENSION
  - Aliskiren
  - Clevelox
  - Darusentan
  - Imidapril
  - Nebivolol
  - PW2101
  - Tadalafil
- INFERTILITY
  - ASSISTED REPRODUCTIVE TECHNOLOGIES
- Table 21 CURRENTLY AVAILABLE ASSISTED REPRODUCTIVE TECHNOLOGIES
- Table 21 (CONTINUED)
- Table 22 U.S. ASSISTED REPRODUCTIVE TECHNOLOGY PROCEDURE VOLUMES, THROUGH 2011
- Table 22 (CONTINUED)
  - Success Rates for ART
- Table 23 U.S. PREGNANCY SUCCESS RATES FOR ART PROCEDURES, 1998
- Table 24 U.S. PREGNANCY SUCCESS RATES FOR ART PROCEDURES, NONDONER EGGS, 2003
- Table 25 U.S. PREGNANCY SUCCESS RATES FOR ART PROCEDURES, DONOR EGGS, 2003
  - Success Rates for ART (Continued)
  - Success Rates for ART (Continued)
    - Semen Processing
    - Intrauterine Insemination
    - In Vitro Fertilization
      - In Vitro Fertilization (Continued)
- Table 26 EFFECT OF PREVIOUS UNSUCCESSFUL IVF ATTEMPTS ON LIVE BIRTH RATE PER CYCLE
- Table 27 EFFECT OF AGE OF WOMAN ON IVF LIVE BIRTH RATE PER CYCLE
- Table 28 EFFECT OF CAUSE OF IVF INFERTILITY ON LIVE BIRTH RATE PER CYCLE
- Table 29 U.S. IN VITRO FERTILIZATION PROCEDURE VOLUMES, THROUGH 2006
  - Ooplasmic Transfer
  - Gamete Intrafallopian Tube Transfer
  - Zygote Intrafallopian Transfer
- Table 30 U.S. GAMETE INTRAFALLOPIAN TRANSFER AND ZYGOTE INTRAFALLOPIAN TRANSFER PROCEDURE VOLUMES, THROUGH 2006
  - Tubal Embryo Transfer
  - Intracytoplasmic Sperm Injection
- U.S. FERTILITY CLINICS SERVE THE WORLD MARKET
- THE FUTURE OF BIOTECH IN REPRODUCTIVE TECHNOLOGY
- LEGAL ENVIRONMENT
- THE INFERTILITY TREATMENT MARKET
  - Current Status of the Infertility Market
  - Fertility Treatment Market Projections
- Table 31 U.S. MARKET FOR INFERTILITY TREATMENT, THROUGH 2011 ($ MILLIONS)
- Table 32 U.S. COSTS OF INFERTILITY DIAGNOSTICS AND TREATMENTS, 2005 ($)
  - FERTILITY DRUGS
- Table 33 SELECTED PHARMACEUTICAL AGENTS FOR THE TREATMENT OF FEMALE INFERTILITY
- Table 33 (CONTINUED)
  - Major Participants in the Fertility Drug Market
- Table 34 MANUFACTURERS OF FERTILITY DRUGS AND THEIR PRODUCTS
- Table 34 (CONTINUED)
  - Genetically Engineered Products Take Over the Market
  - Increasing Focus on the Treatment of Male Infertility
    - Leading Fertility Drugs
- Table 35 LEADING FERTILITY DRUGS BY INDICATION
  - Bromocryptine Mesylate
  - Cetrotide
  - Chlorotriansene
  - Clomiphene Citrate
  - Danazol
  - Estrogens
    - Estradiol Valerate
    - Esterified Estrogens
    - Estrone
    - Estropipate
    - Ethinyl Estradiol
    - Gonadorelin Acetate
  - Gonadotropins
- Table 36 GONADOTROPIN USAGE IN SELECTED COUNTRIES (ESTIMATED NUMBER OF AMPOULES PER 1,000 INHABITANTS)
  - Recombinant Follicle-Stimulating Hormones
    - Recombinant Follicle-...(Continued)
  - Gonadotropin, Chorionic
  - Gonadotropin-Releasing Hormone Antagonist
  - Luteinizing Hormone-Releasing Hormone Antagonist
    - Goserelin Acetate
    - Leuprolide Acetate
  - Menotropins
  - Nafarelin Acetate
  - Ovidrel/Ovitrelle
  - Progesterone
    - Progesterone (Continued)
  - Quinestrol
  - Urofollitropin
    - The Global Market for Fertility Drugs
- Table 37 GLOBAL SALES OF SELECTED FERTILITY DRUGS, THROUGH 2011
- Table 38 GEOGRAPHIC SHARES OF INFERTILITY PHARMACEUTICALS, THROUGH 2011 ($ MILLIONS)
  - Leading Global Marketers of Fertility Drugs
- Figure 8 INFERTILITY DRUGS: GLOBAL SUPPLIER MARKET SHARES, 2005 (PERCENT)
  - Fertility Drugs in Development
- Table 39 FERTILITY DRUGS IN PHASE II OR LATER DEVELOPMENT
  - FSH-CTP
  - Visanne
  - Vitropin
    - Ovarian Implants as a Treatment for Infertility
- THYROID DISEASE
  - HYPERTHYROIDISM
    - Drugs Used to Treat Hyperthyroidism
    - The Market for Drugs to Treat Hyperthyroidism
- Table 40 GLOBAL MARKET FOR PRODUCTS TO TREAT HYPERTHYRODISM, THROUGH 2011 ($ MILLIONS)
  - Products in Development for the Treatment of Hyperthyroidism
- HYPOTHYROIDISM
  - Drugs Used to Treat Hypothyroidism
- Table 41 DRUGS USED TO TREAT HYPOTHYROIDISM
  - Levothyroxine
  - Liothyronine
  - Liotrix
  - Natural Thyroid
    - Synthroid Gains FDA Approval Decades After its Market Introduction
  - The Market for Prescription Drugs to Treat Hypothyroidism
- Table 42 GLOBAL SALES OF SELECTED DRUGS TO TREAT HYPOTHYROIDISM, THROUGH 2011
  - Prescription Products in Development for the Treatment of Hypothyroidism
METABOLIC DISEASES - APPLICATIONS AND PRODUCTS
- HYPERCHOLESTEROLEMIA
  - PRESCRIPTION DRUGS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA
- Table 43 CLASSES OF LIPID-LOWERING DRUGS
- Table 43 (CONTINUED)
  - Bile Acid-Binding Resins
  - Hydroxymethylglutaryl-CoA Reductase Inhibitors
    - U.S. Marketed Statin Drugs
- Table 44 STATIN DRUGS AVAILABLE GLOBALLY AND THEIR GENERIC AVAILABILITY IN THE U.S.
  - Fibric Acids
  - Nicotinic Acid and Derivatives
  - Probucol
  - Currently Marketed Antihyperlipidemic Drugs
- Table 45 ANTIHYPERLIPIDEMIC DRUGS ON THE MARKET
- Table 45 (CONTINUED)
  - Leading Products
  - Combination Products
  - Research and Development
    - Statin Drugs Show Promise in Treating Prostate Cancer
    - The Entry of Generic Versions of Blockbuster Cholesterol Drugs
    - Blockbuster Cholesterol Drugs (Continued)
      - The Medicare (Part D) Drug Benefit and Statin Drugs
  - THE MARKET FOR PRESCRIPTION DRUGS TO TREAT HYPERCHOLESTEROLEMIA
- Table 46 GLOBAL MARKET FOR PRODUCTS TO TREAT HYPERCHOLESTEROLEMIA BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 47 U.S. MARKET FOR PRODUCTS TO TREAT HYPERCHOLESTEROLEMIA, THROUGH 2011 ($ MILLIONS)
  - PRODUCTS IN DEVELOPMENT FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA
- Table 48 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND RELATED CONDITIONS
  - AGI-1067
  - Avasimibe
  - CETi-1
  - ETC-216
  - ETC-588
  - ETC-642
  - FM-VP4
  - KS 01-019
  - Lipitor/Torcetrapib
  - MK-524B
- OBESITY
  - MARKETED DRUGS FOR THE TREATMENT OF OBESITY
    - Meridia
    - Xenical
    - Other Products
  - THE MARKET FOR DRUGS TO TREAT OBESITY
- Table 49 GLOBAL MARKET FOR PRESCRIPTION PRODUCTS TO TREAT OBESITY BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 50 U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT OBESITY, THROUGH 2011 ($ MILLIONS)
  - DRUGS IN DEVELOPMENT FOR THE TREATMENT OF OBESITY
    - Cannabinoid (CB1) Antagonists
- Table 51 DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF OBESITY
  - Acomplia
  - ADP356
  - AOD9604
  - ATL-962
  - Cetilistat
  - CP 945598
  - GI 181771
  - HMR 1426
  - P 57
  - Peptide YY3-36
  - S-2367
  - Symlin
  - Tesofensine
  - TM30338
  - Drugs for Other Indications Prescribed Off-Label for the Treatment of Obesity
  - Discontinued Products in Development
    - GlaxoSmithKline Submits Application for an Over-the-Counter Version of Xenical
COMPANY PROFILES
- ABBOTT LABORATORIES
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
  - CORPORATE STRATEGY
- AMYLIN PHARMACEUTICALS, INC.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
  - CORPORATE STRATEGY
- ARENA PHARMACEUTICALS, INC.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
- Table 52 ARENA PHARMACEUTICALS DRUG-DEVELOPMENT PIPELINE
  - CORPORATE STRATEGY
- ATHEROGENICS, INC.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
  - CORPORATE STRATEGY
- BRISTOL-MYERS SQUIBB
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
  - CORPORATE STRATEGY
- FERRING PHARMACEUTICALS AS
  - BUSINESS OVERVIEW
  - CORPORATE STRATEGY
- GLAXOSMITHKLINE, PLC
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
- KING PHARMACEUTICALS, INC.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
  - CORPORATE STRATEGY
- KOS PHARMACEUTICALS, INC.
  - BUSINESS OVERVIEW
  - PRODUCTS
  - CORPORATE STRATEGY
- MERCK & COMPANY, INC.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
- Table 53 MERCK' S DRUGS IN PHASE II OR LATER DEVELOPMENT
  - CORPORATE STRATEGY
- MYOGEN, INC.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
  - CORPORATE STRATEGY
- NOVARTIS AG
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
  - CORPORATE STRATEGY
- ORGANON INTERNATIONAL
  - BUSINESS OVERVIEW
  - PRODUCTS
  - CORPORATE STRATEGY
- PFIZER CORP.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
  - CORPORATE STRATEGY
- SCHERING-PLOUGH CORP.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
  - CORPORATE STRATEGY
- SERONO S.A.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
- Table 54 SERONO PRODUCTS IN PHASE II OR LATER DEVELOPMENT
  - CORPORATE STRATEGY
LIST OF TABLES
- Summary Table:
- GLOBAL MARKETS FOR PRESCRIPTION DRUGS TO TREAT ENDOCRINE AND METABOLIC DISEASES COVERED IN THIS REPORT, THROUGH 2011 ($ MILLIONS)
- Table 1 HYPOTHALAMIC NEUROHORMONES
- Table 2 EFFECTS OF ANTIHYPERTENSIVE AGENTS ON SELECTED CORONARY RISK FACTORS
- Table 3 CLASSIFICATION OF BLOOD PRESSURE FOR ADULTS AGE 18 YEARS AND OLDER
- Table 4 CLASSIFICATION OF CHRONIC ANOVULATION
- Table 5 LABORATORY EVALUATION OF THYROID DISORDERS
- Table 6 CLASSIFICATION OF HYPERTHYROIDISM
- Table 7 BODY MASS INDEX RATIOS AND CLASSIFICATION OF OBESITY
- Table 8 SELECTED ADRENERGIC INHIBITORS: PRECAUTIONS AND SIDE EFFECTS
- Table 9 GLOBAL MARKET FOR ADRENERGIC INHIBITORS, THROUGH 2011 ($ MILLIONS)
- Table 10 SELECTED ACE INHIBITORS: PRECAUTIONS AND SIDE EFFECTS
- Table 11 GLOBAL MARKET FOR ACE INHIBITORS, THROUGH 2011 ($ MILLIONS)
- Table 12 GLOBAL MARKET FOR ANGIOTENSIN II INHIBITORS, THROUGH 2011 ($ MILLIONS)
- Table 13 SELECTED BETA BLOCKERS: PRECAUTIONS AND SIDE EFFECTS
- Table 14 GLOBAL MARKET FOR BETA BLOCKERS, THROUGH 2011 ($ MILLIONS)
- Table 15 SELECTED CALCIUM CHANNEL BLOCKERS: PRECAUTIONS AND SIDE EFFECTS
- Table 16 GLOBAL MARKET FOR CALCIUM CHANNEL BLOCKERS, THROUGH 2011 (MILLIONS)
- Table 17 GLOBAL MARKET FOR COMBINATION ANTIHYPERTENSIVE DRUGS, THROUGH 2011 ($ MILLIONS)
- Table 18 GLOBAL MARKET FOR SELECTED PRESCRIPTION PRODUCTS TO TREAT HYPERTENSION BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 19 U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT HYPERTENSION, THROUGH 2011 ($ MILLIONS)
- Table 20 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF HYPERTENSION
- Table 21 CURRENTLY AVAILABLE ASSISTED REPRODUCTIVE TECHNOLOGIES
- Table 22 U.S. ASSISTED REPRODUCTIVE TECHNOLOGY PROCEDURE VOLUMES, THROUGH 2011
- Table 23 U.S. PREGNANCY SUCCESS RATES FOR ART PROCEDURES, 1998
- Table 24 U.S. PREGNANCY SUCCESS RATES FOR ART PROCEDURES, NONDONER EGGS, 2003
- Table 25 U.S. PREGNANCY SUCCESS RATES FOR ART PROCEDURES, DONOR EGGS, 2003
- Table 26 EFFECT OF PREVIOUS UNSUCCESSFUL IVF ATTEMPTS ON LIVE BIRTH RATE PER CYCLE
- Table 27 EFFECT OF AGE OF WOMAN ON IVF LIVE BIRTH RATE PER CYCLE
- Table 28 EFFECT OF CAUSE OF IVF INFERTILITY ON LIVE BIRTH RATE PER CYCLE
- Table 29 U.S. IN VITRO FERTILIZATION PROCEDURE VOLUMES, THROUGH 2006
- Table 30 U.S. GAMETE INTRAFALLOPIAN TRANSFER AND ZYGOTE INTRAFALLOPIAN TRANSFER PROCEDURE VOLUMES, THROUGH 2006
- Table 31 U.S. MARKET FOR INFERTILITY TREATMENT, THROUGH 2011 ($ MILLIONS)
- Table 32 U.S. COSTS OF INFERTILITY DIAGNOSTICS AND TREATMENTS, 2005 ($)
- Table 33 SELECTED PHARMACEUTICAL AGENTS FOR THE TREATMENT OF FEMALE INFERTILITY
- Table 34 MANUFACTURERS OF FERTILITY DRUGS AND THEIR PRODUCTS
- Table 35 LEADING FERTILITY DRUGS BY INDICATION
- Table 36 GONADOTROPIN USAGE IN SELECTED COUNTRIES (ESTIMATED NUMBER OF AMPOULES PER 1,000 INHABITANTS)
- Table 37 GLOBAL SALES OF SELECTED FERTILITY DRUGS, THROUGH 2011
- Table 38 GEOGRAPHIC SHARES OF INFERTILITY PHARMACEUTICALS, THROUGH 2011 ($ MILLIONS)
- Table 39 FERTILITY DRUGS IN PHASE II OR LATER DEVELOPMENT
- Table 40 GLOBAL MARKET FOR PRODUCTS TO TREAT HYPERTHYRODISM, THROUGH 2011 ($ MILLIONS)
- Table 41 DRUGS USED TO TREAT HYPOTHYROIDISM
- Table 42 GLOBAL SALES OF SELECTED DRUGS TO TREAT HYPOTHYROIDISM, THROUGH 2011
- Table 43 CLASSES OF LIPID-LOWERING DRUGS
- Table 44 STATIN DRUGS AVAILABLE GLOBALLY AND THEIR GENERIC AVAILABILITY IN THE U.S.
- Table 45 ANTIHYPERLIPIDEMIC DRUGS ON THE MARKET
- Table 46 GLOBAL MARKET FOR PRODUCTS TO TREAT HYPERCHOLESTEROLEMIA BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 47 U.S. MARKET FOR PRODUCTS TO TREAT HYPERCHOLESTEROLEMIA, THROUGH 2011 ($ MILLIONS)
- Table 48 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND RELATED CONDITIONS
- Table 49 GLOBAL MARKET FOR PRESCRIPTION PRODUCTS TO TREAT OBESITY BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 50 U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT OBESITY, THROUGH 2011 ($ MILLIONS)
- Table 51 DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF OBESITY
- Table 52 ARENA PHARMACEUTICALS DRUG-DEVELOPMENT PIPELINE
- Table 53 MERCK' S DRUGS IN PHASE II OR LATER DEVELOPMENT
- Table 54 SERONO PRODUCTS IN PHASE II OR LATER DEVELOPMENT
LIST OF FIGURES
- Summary Figure:
- GLOBAL MARKETS FOR PRESCRIPTION DRUGS TO TREAT ENDOCRINE AND METABOLIC DISEASES COVERED IN THIS REPORT, THROUGH 2011 ($ MILLIONS)
- Figure 1 GLOBAL MARKET FOR ADRENERGIC INHIBITORS, 2004-2011 ($ MILLIONS)
- Figure 2 GLOBAL MARKET FOR ACE INHIBITORS, 2004-2011 ($ MILLIONS)
- Figure 3 GLOBAL MARKET FOR ANGIOTENSIN II INHIBITORS, 2004-2011 ($ MILLIONS)
- Figure 4 GLOBAL MARKET FOR BETA BLOCKERS, 2004-2011 ($ MILLIONS)
- Figure 5 GLOBAL MARKET FOR CALCIUM CHANNEL BLOCKERS, 2004-2011 ($ MILLLIONS)
- Figure 6 GLOBAL MARKET FOR COMBINATION ANTIHYPERTENSIVE DRUGS, 2004-2011 ($ MILLIONS)
- Figure 7 U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT HYPERTENSION, 2004-2011 ($ MILLIONS)
- Figure 8 INFERTILITY DRUGS: GLOBAL SUPPLIER MARKET SHARES, 2005 (PERCENT)

主な内分泌疾患および代謝性疾患の薬物治療動向

Drug Treatments for Leading Endocrine and Metabolic Diseases

Abstract

INTRODUCTION

SCOPE OF STUDY

METHODOLOGY

INFORMATION SOURCES

Table of Contents